- Recommendation ID
- NG238/3
- Question
What is the effectivness of stains and/or other lipid-lowering treatment in people with type 1 diabetes?
- Any explanatory notes
(if applicable) For a short explanation of why the committee made this recommendation for research, see the rationale section on statins for primary prevention of CVD .
Full details of the evidence and the committee's discussion are in evidence review C: statins: efficacy and adverse effects.
Source guidance details
- Comes from guidance
- Cardiovascular disease: risk assessment and reduction, including lipid modification
- Number
- NG238
- Date issued
- December 2023
Other details
Is this a recommendation for the use of a technology only in the context of research? | No |
Is it a recommendation that suggests collection of data or the establishment of a register? | No |
Last Reviewed | 01/01/2024 |